Vertex Pharmaceuticals (NASDAQ:VRTX) reported quarterly earnings of $4.73 per share which met the analyst consensus estimate. This is a 4.65 percent increase over earnings of $4.52 per share from the same period last year. The company reported quarterly sales of $3.334 billion which beat the analyst consensus estimate of $3.232 billion by 3.15 percent. This is a 12.45 percent increase over sales of $2.965 billion the same period last year.